Antifungal Agents and Infrared Thermotherapy Alone or in Combination in the Treatment of Sporotrichosis

Launched by FIRST HOSPITAL OF CHINA MEDICAL UNIVERSITY · Mar 7, 2024

Keywords

ClinConnect Summary

This clinical trial is investigating new ways to treat sporotrichosis, a fungal infection that can cause serious health problems. Researchers want to see if using antifungal medications along with a treatment called infrared thermotherapy (which uses heat) either separately or together can help fight this infection. They believe that applying heat can change certain immune cells in the body to become more effective at attacking the fungus. The study aims to understand how this process works and whether it can improve treatment outcomes for patients with sporotrichosis.

To participate in the trial, individuals must have a confirmed diagnosis of sporotrichosis through specific tests and be able to give their consent to join the study. They should also be in good enough health to cooperate with the treatment. However, people who have had certain recent treatments for fungal infections or have specific health conditions might not be eligible. Participants can expect to receive either antifungal medications, infrared thermotherapy, or a combination of both, and the researchers will closely monitor their progress to gather important data on the effectiveness of these treatments.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • The results of pathology and fungal culture were all patients with sporotrichosis.
• • Informed consent to the purpose and content of the study, and follow-up as required
• • The physical condition and self-condition can cooperate with the treatment.
• Exclusion Criteria:
• • Subjects who are unable to maintain a relatively stable posture during treatment.
• • Those who are sensitive or allergic to this experimental drug.
• • Systemic antifungal or KI therapy within 12 months
• • Local antifungal therapy within 1 month.
• • Previous history of immunodeficiency virus (HIV) infection, or positive HIV antibody in screening period.